Literature DB >> 31512100

Surgical Treatment for Refractory Gastroparesis: Stimulator, Pyloric Surgery, or Both?

Bryan Zoll1, Asad Jehangir1, Michael A Edwards2, Roman Petrov3, William Hughes1, Zubair Malik1, Henry P Parkman4.   

Abstract

BACKGROUND: Several surgical options exist for refractory gastroparesis (Gp) including gastric electric stimulation (GES) and pyloric surgery (PS) such as pyloromyotomy or pyloroplasty. Few studies exist comparing the outcomes of these surgeries. AIM: Compare the clinical outcomes of GES, PS, and simultaneous GES+PS for refractory Gp.
METHODS: Patients undergoing surgical intervention at our medical center from January 2016 to April 2019 were given pre- and post-surgery questionnaires to assess their response to intervention: Patient Assessment of Upper Gastrointestinal Symptoms (PAGI-SYM) grading symptoms and Clinical Patient Grading Assessment Scale (CPGAS) grading response to treatment. Results are expressed as mean ± SE.
RESULTS: One hundred thirty-two patients underwent surgical intervention; 12 were excluded. Mean CPGAS improvement overall was 2.8 ± 0.2 (p < 0.01): GES+PS had CPGAS score at 3.6 ± 0.5, pyloric interventions 3.1 ± 0.5, and GES 2.5 ± 0.4 (p > 0.05). Mean improvement in Gastroparesis Cardinal Symptom Index (GCSI) total score was 1.0 ± 0.1 (p < 0.01), with improvement of 1.1 ± 0.2 for GES + PS, 0.9 ± 0.2 for GES, and 0.9 ± 0.2 for PS (p > 0.05). GES and GES + PS, but not PS only, significantly improved symptoms of nausea and vomiting (p < 0.01). Among gastroparesis subtypes, patients with diabetic gastroparesis had more improvement on nausea/vomiting subscale compared with idiopathic gastroparesis (p = 0.028).
CONCLUSIONS: Patients with refractory symptoms of Gp undergoing GES, PS, or combined GES+PS each had significant improvement of their GCSI total score. GES and combined GES+PS significantly improved nausea/vomiting. These results suggest GES or combined GES+PS appears better for nausea/vomiting predominant refractory Gp.

Entities:  

Keywords:  Gastric electric stimulation; Gastroparesis; Pyloromyotomy; Pyloroplasty

Mesh:

Year:  2019        PMID: 31512100     DOI: 10.1007/s11605-019-04391-x

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  7 in total

Review 1.  Endoscopic and Surgical Treatments for Gastroparesis: What to Do and Whom to Treat?

Authors:  Roman V Petrov; Charles T Bakhos; Abbas E Abbas; Zubair Malik; Henry P Parkman
Journal:  Gastroenterol Clin North Am       Date:  2020-06-20       Impact factor: 3.806

Review 2.  Gastric Electrical Stimulation: Role and Clinical Impact on Chronic Nausea and Vomiting.

Authors:  Heithem Soliman; Guillaume Gourcerol
Journal:  Front Neurosci       Date:  2022-05-10       Impact factor: 5.152

3.  EndoFLIP and Pyloric Dilation for Gastroparesis Symptoms Refractory to Pyloromyotomy/Pyloroplasty.

Authors:  Asad Jehangir; Zubair Malik; Roman V Petrov; Henry P Parkman
Journal:  Dig Dis Sci       Date:  2020-08-04       Impact factor: 3.199

4.  Both gastric electrical stimulation and pyloric surgery offer long-term symptom improvement in patients with gastroparesis.

Authors:  Sarah Marowski; Yiwei Xu; Jake A Greenberg; Luke M Funk; Anne O Lidor; Amber L Shada
Journal:  Surg Endosc       Date:  2020-10-06       Impact factor: 4.584

5.  Absorbable antibacterial envelope in the surgical management of Twiddler's syndrome in a patient with gastric electric stimulator: a case report.

Authors:  Miranda Haslam; Henry P Parkman; Roman V Petrov
Journal:  Dig Med Res       Date:  2020-12

6.  Characteristics of patients who underwent gastric electrical stimulation vs. surgical pyloric interventions for refractory gastroparesis.

Authors:  Saad Saleem; Azhar Hussain; Mohd A Alsamman; Faisal Inayat; Jasndeep Kaler; Aylin Tansel; Abell L Thomas
Journal:  Saudi J Gastroenterol       Date:  2021 Sep-Oct       Impact factor: 2.485

Review 7.  Nausea and Vomiting in 2021: A Comprehensive Update.

Authors:  Matthew Heckroth; Robert T Luckett; Chris Moser; Dipendra Parajuli; Thomas L Abell
Journal:  J Clin Gastroenterol       Date:  2021-04-01       Impact factor: 3.174

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.